SCHEMBL20119613

SCHEMBL20119613

Clc1nc(NCc2ccco2)c2nc(-c3cccnc3)[nH]c2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
ALDH1A1 P00352 5/20 0.51
MAPK1 P28482 5/20 0.51
PDE5A O76074 3/20 0.51
HSD17B10 Q99714 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TSHR P16473 2/20 0.51
GAA P10253 1/20 0.51
CLK1 P49759 1/20 0.51
HBB P68871 1/20 0.51
HPGD P15428 1/20 0.48
FYN P06241 1/20 0.45
KMT2A Q03164 7/20 0.42
KDM4E B2RXH2 3/20 0.42
F2 P00734 2/20 0.42
MEN1 O00255 3/20 0.40
RECQL P46063 1/20 0.40
USP2 O75604 1/20 0.40
REN P00797 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119897 0.88 SMN1; SMN2 (0.51) MAPTALDH1A1MAPK1PDE5AHSD17B10
SCHEMBL20119901 0.78 SMN1; SMN2 (0.54) MAPTALDH1A1MAPK1HSD17B10SMN1; SMN2
SCHEMBL20119969 0.78 SMN1; SMN2 (0.54) MAPTALDH1A1MAPK1HSD17B10SMN1; SMN2
SCHEMBL20119700 0.76 SMN1; SMN2 (0.47) MAPTALDH1A1MAPK1PDE5AHSD17B10
SCHEMBL20119584 0.76 SMN1; SMN2 (0.52) MAPTALDH1A1MAPK1PDE5AHSD17B10
SCHEMBL20119685 0.76 SMN1; SMN2 (0.52) MAPTALDH1A1MAPK1HSD17B10SMN1; SMN2
SCHEMBL20119887 0.75 SMN1; SMN2 (0.51) MAPTALDH1A1MAPK1HSD17B10SMN1; SMN2
SCHEMBL20119668 0.75 SMN1; SMN2 (0.51) MAPTALDH1A1MAPK1PDE5AHSD17B10
SCHEMBL20119630 0.75 SMN1; SMN2 (0.51) MAPTALDH1A1MAPK1HSD17B10SMN1; SMN2
SCHEMBL20119938 0.75 SMN1; SMN2 (0.51) MAPTALDH1A1MAPK1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885MAPK1 4547/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885MAPK1 4547/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885MAPK1 4547/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885MAPK1 4547/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885MAPK1 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.